TNFAIP3 and primary central nervous system lymphoma: Additionally, mutations in CARD11 and TNFAIP3, which operate downstream of BTK, have been identified as potential sources of resistance to ibrutinib in both systemic lymphoma (74) and PCNSL treated with ibrutinib monotherapy (3).